Samsung Bioepis signs Teva partnership for SB41, SB44 biosimilars development and commercialization

Bitget2026/10/01 09:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Samsung Bioepis signed an early-stage partnership with Teva to develop SB41 and SB44 biosimilars for commercialization.
Bioepis will handle development, manufacturing, supply; Teva will lead sales in the US, Europe, Canada.
Agreement signed Sept. 30, 2026; contract term and value were not disclosed.
Bioepis expects receipts of at least KRW 41.8 billion, based on a 2.5% disclosure threshold versus 2025 financials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung EPIS Holdings Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261001800667), on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Samsung Bioepis signs Teva partnership for SB41, SB44 biosimilars development and commercialization

You may also like

Crypto prices